As “time-to-result” is crucial to improve clinical outcome, diagnostic tests that deliver fast results and that are easy to use are essential. Cube Dx’s technology is based on multiplexed diagnostics tailor-made for clinical application.
This methodology is based on Cube Dx’s cylindrical microarray – the hybcell. DNA oligos are immobilized on the surface of a cylinder. This cylinder is enclosed within a container which is filled with sample. The hybcell is processed by a fully automated device. In a first step the sequence enclosing the genes of interest (e.g. bacterial S16) is amplified by PCR. Concurrently one of the DNA strands is labeled with a fluorescent marker. The amplicons are transferred into the hybcell, where they hybridize to the immobilized probes, differing in only a single base on their 3’ end. A highly specific polymerase assures extension only if the last base is complementary to the amplicon. The translation of results will be covered by at least two test prototypes: a) a DNA test for identification of pathogens/pathogen traits (e.g. S. pyogenes, S. aureus, toxins, antibiotic resistances) and b) an antibody test to identify the disease and host (patient) status. The latter will initially target spectrum of candidate markers that have been implicated in tissue pathology. This will be revised as new sets of host factors associated with NSTIs are discovered by the work in WP1, 2, 3, 4, 5 and 6.